No Data
Henan Lingrui Pharmaceutical (SHSE:600285) Could Easily Take On More Debt
Henan Lingrui Pharmaceutical discloses a stock-based incentive plan Unveiling conditions: average annual double-digit growth in non-GAAP net income | Speed reading announcement
①Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, slightly lowering the assessment target compared to the previous incentive plan, but still maintaining a double-digit non-GAAP performance assessment requirement. ②In addition to Henan Lingrui Pharmaceutical, tibet cheezheng tibetan medicine has also previously announced an employee stock ownership plan with higher assessment targets, and the industry expects bone health to be a high-potential category in the out-of-hospital market.
Henan Lingrui Pharmaceutical (600285.SH): Plans to use no more than 2.2 billion yuan of idle self-owned funds for cash management.
Henan Lingrui Pharmaceutical (600285.SH) announced on November 29 that on November 29, 2024, the company held the twelfth meeting of the ninth board of directors and the tenth meeting of the ninth board of supervisors, and approved the "Proposal on Authorizing the Use of Idle Own Funds for Money Management", agreeing to use idle own funds not exceeding RMB 2.2 billion for cash management, with funds within the quota available for rolling use.
henan lingrui pharmaceutical (600285.SH): plans to launch 1.25 million restricted stocks incentive plan.
On November 29, Gelonghui reported that Henan Lingrui Pharmaceutical (600285.SH) announced the 2024 restricted stock incentive plan. The number of restricted stocks proposed to be granted to the incentive objects is 1.25 million shares, which accounts for approximately 0.22% of the company's total share capital of 567,115,486 shares on the announcement date of this incentive plan draft. This grant is a one-time grant with no reserved rights. The total number of recipients for the restricted stocks granted under this incentive plan is 9, and the grant price for the restricted stocks is 10.96 yuan per share.
Lingrui Pharmaceutical Gets Nod for Mupirocin Ointment's Registration; Shares Up 4%
henan lingrui pharmaceutical (600285.SH): Mupirocin ointment obtained pharmaceutical registration certificate
On November 6th, Gelonhui reported that Henan Lingrui Pharmaceutical (600285.SH) recently received the Drug Registration Certificate for mupirocin ointment issued by the National Medical Products Administration. Mupirocin ointment is a topical antibiotic suitable for skin infections caused by gram-positive cocci, such as primary skin infections like pyoderma, furuncle, folliculitis, as well as secondary skin infections like eczema with infection, ulcers with infection, wounds with infection, etc.
Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?No Data
No Data
